Efficacy of paclitaxel in the treatment of Kaposi sarcoma
Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its systemic treatment, in addition to some chemotherapeutics, taxanes have also been used during the recent years for their anti-angiogenic prop...
Saved in:
Published in | European review for medical and pharmacological sciences Vol. 19; no. 21; p. 4095 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
01.11.2015
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its systemic treatment, in addition to some chemotherapeutics, taxanes have also been used during the recent years for their anti-angiogenic properties. In this study, we aimed to compare paclitaxel and non-paclitaxel chemotherapeutic regimens in terms of efficacy and side effects.
In our center, demographical, clinical and histopathological characteristics of a total of 13 patients diagnosed with Kaposi sarcoma who received therapy were retrospectively recorded based on their medical files
Among these subjects, 7 have been treated with paclitaxel and 6 with non-paclitaxel therapies. Eleven patients were male. Twelve patients were found to have classical type of Kaposi Sarcoma. The recurrence was observed in 2 patients treated with paclitaxel and in 1 patient treated with non-paclitaxel therapy. No statistically significant difference was found between the therapeutic modality, the stage of the disease and the percentage of the recurrence. Neuropathy developed in 3 patients treated with paclitaxel, whereas there was no neuropathy in the other group. Although the recurrence-free survival was worse in the patients treated with paclitaxel, there was no statistically significant difference.
Cytotoxic chemotherapy is effective in treating patients with Kaposi Sarcoma, although it is palliative. Taxanes have demonstrated effectiveness against AIDS-associated Kaposi Sarcoma. The experience suggests that paclitaxel is an effective alternative in the treatment of classical form Kaposi's sarcoma. There was no difference in efficacy between paclitaxel and non-paclitaxel therapies whereas difference in occurrence of neuropathy which is one of the side effects, showed borderline statistical significance. |
---|---|
AbstractList | Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its systemic treatment, in addition to some chemotherapeutics, taxanes have also been used during the recent years for their anti-angiogenic properties. In this study, we aimed to compare paclitaxel and non-paclitaxel chemotherapeutic regimens in terms of efficacy and side effects.
In our center, demographical, clinical and histopathological characteristics of a total of 13 patients diagnosed with Kaposi sarcoma who received therapy were retrospectively recorded based on their medical files
Among these subjects, 7 have been treated with paclitaxel and 6 with non-paclitaxel therapies. Eleven patients were male. Twelve patients were found to have classical type of Kaposi Sarcoma. The recurrence was observed in 2 patients treated with paclitaxel and in 1 patient treated with non-paclitaxel therapy. No statistically significant difference was found between the therapeutic modality, the stage of the disease and the percentage of the recurrence. Neuropathy developed in 3 patients treated with paclitaxel, whereas there was no neuropathy in the other group. Although the recurrence-free survival was worse in the patients treated with paclitaxel, there was no statistically significant difference.
Cytotoxic chemotherapy is effective in treating patients with Kaposi Sarcoma, although it is palliative. Taxanes have demonstrated effectiveness against AIDS-associated Kaposi Sarcoma. The experience suggests that paclitaxel is an effective alternative in the treatment of classical form Kaposi's sarcoma. There was no difference in efficacy between paclitaxel and non-paclitaxel therapies whereas difference in occurrence of neuropathy which is one of the side effects, showed borderline statistical significance. |
Author | Duman, B B Afsar, C U Ercolak, V Gunaldi, M Sahin, B |
Author_xml | – sequence: 1 givenname: V surname: Ercolak fullname: Ercolak, V email: vehbiercolak@hotmail.com organization: Department of Medical Oncology, Cukurova University Medical Faculty, Adana, Turkey. vehbiercolak@hotmail.com – sequence: 2 givenname: B surname: Sahin fullname: Sahin, B – sequence: 3 givenname: M surname: Gunaldi fullname: Gunaldi, M – sequence: 4 givenname: B B surname: Duman fullname: Duman, B B – sequence: 5 givenname: C U surname: Afsar fullname: Afsar, C U |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26592833$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKBDEQAIMouq7-guQHBiavSecoy_rABS96XjqZbgzMI8xEcP9eRD3VoaCgrsX5NE90JjZag21ar8OluNKdCxqM2YiwZ84J00nOLAumIVf8okHmSdYPknUhrCNN9Ue_YJnXLFdc0jzijbhgHFa6_eNWvD_s33ZPzeH18Xl3f2iK8lCbPmKrolLBGo7gwCYDkX3wBlD5lpyhng1w6jyBcsidDza6YHvfRjBBb8Xdb7d8xpH6Y1nyiMvp-P-gvwESq0AK |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 2284-0729 |
ExternalDocumentID | 26592833 |
Genre | Journal Article |
GroupedDBID | CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-p178t-dba01b11943fb8584c38bf79738a170e53edf38fc67e815af6794b594d70b8392 |
IngestDate | Sun Apr 30 12:08:42 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 21 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p178t-dba01b11943fb8584c38bf79738a170e53edf38fc67e815af6794b594d70b8392 |
PMID | 26592833 |
ParticipantIDs | pubmed_primary_26592833 |
PublicationCentury | 2000 |
PublicationDate | 2015-11-01 |
PublicationDateYYYYMMDD | 2015-11-01 |
PublicationDate_xml | – month: 11 year: 2015 text: 2015-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Italy |
PublicationPlace_xml | – name: Italy |
PublicationTitle | European review for medical and pharmacological sciences |
PublicationTitleAlternate | Eur Rev Med Pharmacol Sci |
PublicationYear | 2015 |
Score | 2.1258566 |
Snippet | Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 4095 |
SubjectTerms | Adult Aged Antineoplastic Agents, Phytogenic - therapeutic use Female Follow-Up Studies Humans Male Middle Aged Neoplasm Recurrence, Local - diagnosis Paclitaxel - administration & dosage Paclitaxel - therapeutic use Retrospective Studies Sarcoma, Kaposi - diagnosis Sarcoma, Kaposi - drug therapy Treatment Outcome |
Title | Efficacy of paclitaxel in the treatment of Kaposi sarcoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26592833 |
Volume | 19 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA5WL15E8f1iD94ksuk-snv0USlKi2ALvZUkm8Fiuy3YgvjrnWSz3baoqJcQMiGw-bKTyWTmCyEXIgJQqQQaZyqmoVR1KtHsoICLI8aa5pZKqdWOm93woRf1qlc6bXbJVF6pjy_zSv6DKrYhriZL9g_IzgfFBqwjvlgiwlj-CuOG4X8w77WbsGWhDN_2ux6WoYtVDDmKH4UJz7p8w3U9dqp41R_vslhM3OHIXd9YFoGK3LpKoVRV6GEDRxyK16WA2Wfx4t6Bn8f3zIwPerDkf72bOffrjevnvA8scml4dvOwWqqO-xs19ONLKjVdWDpFBrRTkHicjBY1N07oZGThqZsL3qRgxfhZukKQXYpqpMYTo-TaTy3D8eyaV84L1m7obJMtZ_B71wV6O2RN57skLZHzxuBVyHmD3EPkvDlyRlwg5znk9kj3vtG5bVL3iAWdMJ5MaSaFzyRjaRiATNDcU0Eigac8SATjvo4CnUGQgIq5TlgkIEYNKaM0zLgvjfW6T9bzca4PiYe9_AA08MicMxkICABCkarQB4lm2xE5KL60PymYSvrlHBx_KzkhmxWsp2QD8NfQZ2hnTeW5nclPx4EuBg |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+paclitaxel+in+the+treatment+of+Kaposi+sarcoma&rft.jtitle=European+review+for+medical+and+pharmacological+sciences&rft.au=Ercolak%2C+V&rft.au=Sahin%2C+B&rft.au=Gunaldi%2C+M&rft.au=Duman%2C+B+B&rft.date=2015-11-01&rft.eissn=2284-0729&rft.volume=19&rft.issue=21&rft.spage=4095&rft_id=info%3Apmid%2F26592833&rft_id=info%3Apmid%2F26592833&rft.externalDocID=26592833 |